Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4
4 · Verve Therapeutics, Inc. · Filed Jun 22, 2021
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2021-06-21+1,343,081→ 1,343,081 total - Conversion
Common Stock
2021-06-21+1,152,490→ 2,495,571 total - Conversion
Series A-2 Preferred Stock
2021-06-21−12,436,264→ 0 total→ Common Stock (1,343,081 underlying) - Conversion
Series B Preferred Stock
2021-06-21−10,671,482→ 0 total→ Common Stock (1,152,490 underlying)
Footnotes (2)
- [F1]The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date.
- [F2]The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.